loading page

Non-viral siRNA delivery systems for pancreatic cancer therapy
  • +4
  • Shahin aghamiri,
  • Alireza Teymouri,
  • Samira Mohammadi‐Yeganeh,
  • Shiva Bayat,
  • Delsuz Rezaee ,
  • Afshin Abdi Ghavidel,
  • Hossein Ghanbarian
Shahin aghamiri
Shahid Beheshti University of Medical Sciences
Author Profile
Alireza Teymouri
Tehran University of Medical Sciences
Author Profile
Samira Mohammadi‐Yeganeh
Shahid Beheshti University of Medical Sciences
Author Profile
Shiva Bayat
Tehran University of Medical Sciences
Author Profile
Delsuz Rezaee
Shahid Beheshti University of Medical Sciences
Author Profile
Afshin Abdi Ghavidel
Shahid Beheshti University of Medical Sciences
Author Profile
Hossein Ghanbarian
Shahid Beheshti University of Medical Sciences
Author Profile

Abstract

The serious drawbacks of conventional pancreatic ductal adenocarcinoma (PDAC) therapy like nonspecific toxicity and high resistance to chemo and radiation therapy, prompted the development and application of countless siRNA-based therapeutics. Significant technological success has been achieved in this area; however, the major challenges to siRNA-based therapeutics becoming a new paradigm in the pancreatic cancer therapy stem from enzymatic digestion, off-target effects, difficulty to enter cells, induction of innate immune responses, and renal clearance. Recent advances in drug delivery systems hold great promise for improving siRNA-based therapeutics and developing a new class of drugs, nano-siRNA drugs. However, a number of fundamental questions, regarding toxicity, immunostimulation, and poor knowledge of nano-bio interactions, need to be addressed before clinical translation. In this review, we provide recent achievements in designing and development of various non-viral delivery vehicles for pancreatic cancer therapy. More importantly, co-delivery of conventional anticancer drugs with siRNA as a new revolutionary pancreatic cancer combinational therapy is completely discussed.

Peer review status:ACCEPTED

04 Oct 2020Submitted to Biotechnology and Bioengineering
05 Oct 2020Submission Checks Completed
05 Oct 2020Assigned to Editor
17 Nov 2020Reviewer(s) Assigned
23 Apr 2021Review(s) Completed, Editorial Evaluation Pending
23 Apr 2021Editorial Decision: Revise Minor
17 Jun 20211st Revision Received
17 Jun 2021Submission Checks Completed
17 Jun 2021Assigned to Editor
19 Jun 2021Review(s) Completed, Editorial Evaluation Pending
19 Jun 2021Editorial Decision: Accept